Gly-β-MCA

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

Product information

CAS Number: 66225-78-3

Molecular Weight: 465.62

Formula: C26H43NO6

Chemical Name: 2-[(4R)-4-[(1R,3aS,3bS,4R,5S,5aR,7R,9aR,9bS,11aR)-1,3a,3b,9b-tetrahydrogenio-4,5,7-trihydroxy-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]pentanamido]acetic acid

Smiles: C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1[C@H](O)[C@@H]3O

InChiKey: ZQYUKJFJPJDMMR-IIWZPVADSA-N

InChi: InChI=1S/C26H43NO6/c1-14(4-7-20(29)27-13-21(30)31)16-5-6-17-22-18(9-11-25(16,17)2)26(3)10-8-15(28)12-19(26)23(32)24(22)33/h14-19,22-24,28,32-33H,4-13H2,1-3H3,(H,27,29)(H,30,31)/t14-,15-,16-,17+,18+,19+,22+,23+,24-,25-,26-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (214.77 mM; Need ultrasonic). H2O : < 0.1 mg/mL (ultrasonic) (insoluble).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Gly-β-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor. Gly-β-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH.

In Vivo:

Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice. Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation.

References:

1. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.

Products are for research use only. Not for human use.